Story perspectives
UK Approves Zurzuvae for Postnatal Depression Treatment
8/28/2025
23 5
1 of 1
Story summary
- The UK’s Medicines and Healthcare products Regulatory Agency approved Biogen's Zuranolone, branded as Zurzuvae, for postnatal depression.
- The treatment is administered nightly for 14 days and may cause side effects such as memory impairment and fatigue.
- Postnatal depression impacts more than 10% of women within one year of giving birth.
